...
首页> 外文期刊>Allergy >H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review.
【24h】

H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review.

机译:H1-抗组胺药治疗过敏反应:Cochrane系统评价。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Anaphylaxis is an acute systemic allergic reaction, which can be life-threatening. H(1)-antihistamines are commonly used as an adjuvant therapy in the treatment of anaphylaxis. We sought to assess the benefits and harm of H(1)-antihistamines in the treatment of anaphylaxis. METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library); MEDLINE (1966 to June 2006); EMBASE (1966 to June 2006); CINAHL (1982 to June 2006) and ISI Web of Science (1945 to July 2006). We also contacted pharmaceutical companies and international experts in anaphylaxis in an attempt to locate unpublished material. Randomized and quasi-randomized-controlled trials comparing H(1)-antihistamines with placebo or no intervention were eligible for inclusion. Two authors independently assessed articles for inclusion. RESULTS: We found no studies that satisfied the inclusion criteria. CONCLUSIONS: Based on this review, we are unable to make any recommendations for clinical practice.Randomized-controlled trials are needed, although these are likely to prove challenging to design and execute.
机译:背景:过敏反应是一种急性全身性过敏反应,可能危及生命。 H(1)-antihistamines通常用作辅助治疗的过敏反应。我们试图评估H(1)-抗组胺药在过敏反应治疗中的益处和危害。方法:我们搜索了Cochrane对照试验中央登记册(中央,Cochrane图书馆); MEDLINE(1966年至2006年6月); EMBASE(1966年至2006年6月); CINAHL(1982年至2006年6月)和ISI Web of Science(1945年至2006年7月)。我们还联系了过敏反应的制药公司和国际专家,以查找未发表的材料。比较H(1)-抗组胺药与安慰剂或无干预的随机和半随机对照试验符合纳入条件。两位作者独立评估了文章的收录性。结果:我们发现没有满足纳入标准的研究。结论:基于本综述,我们无法对临床实践提出任何建议,尽管随机对照试验可能对设计和执行具有挑战性,但仍需要进行随机对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号